Denali Therapeutics (NASDAQ:DNLI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other research firms also recently commented on DNLI. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a report on Friday. Deutsche Bank Aktiengesellschaft upped their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research note on Monday, June 22nd. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $35.92.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $25.00 on Friday. The stock has a 50 day moving average price of $23.63 and a 200 day moving average price of $21.35. Denali Therapeutics has a 52 week low of $12.58 and a 52 week high of $27.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The stock has a market capitalization of $3.97 billion, a PE ratio of -8.80 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter last year, the business earned ($0.72) earnings per share. Analysts predict that Denali Therapeutics will post -2.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Denali Therapeutics in the 2nd quarter valued at $26,000. Global Retirement Partners LLC acquired a new stake in Denali Therapeutics during the 2nd quarter valued at $28,000. Headlands Technologies LLC bought a new position in Denali Therapeutics during the second quarter worth $26,000. Johnson Financial Group Inc. bought a new position in Denali Therapeutics during the third quarter worth $29,000. Finally, State of Wyoming acquired a new position in shares of Denali Therapeutics in the second quarter valued at $29,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.